20-F: ALR Technologies 2025 Annual Report: Financial Challenges

ALR Technologies reports significant net losses and substantial doubt regarding its ability to continue as a going concern for the 2025 fiscal year.

Summary

• Reported a net loss of $22,057,792 for the fiscal year ended December 31, 2025, compared to $15,877,514 in 2024.
• Accumulated deficit reached $158,043,706 as of December 31, 2025.
• Generated $Nil in revenue for 2025 and 2024, down from $25,536 in 2023.
• Working capital deficiency of $39,858,629 reported at year-end 2025.
• Total current liabilities of $39,906,003, with significant portions owed to the CEO, his family, and related entities.
• Entered into a new manufacturing agreement with CGM Medical Technology Shen Zhen Ltd. (CMTS) on September 19, 2025, for GluCurve Pet CGM hardware.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as highly negative due to the severe going concern warning, lack of revenue, and extreme reliance on related-party debt.

Positives

• Secured a manufacturing agreement with CMTS for GluCurve Pet CGM hardware, providing a path toward potential commercialization.
• Maintained access to line of credit facilities from related parties to fund ongoing operations.
• Continued development of the Diabetes Solution and GluCurve Pet CGM product lines.

Negatives

• Recurring net losses and negative cash flow raise substantial doubt about the ability to continue as a going concern.
• Revenue generation has been negligible, with $Nil revenue reported for the last two fiscal years.
• Significant debt burden, with $33,199,000 owed to the Chairman/CEO, his family, and controlled entities as of December 31, 2025.
• Material weakness in internal control over financial reporting identified due to insufficient written policies and procedures.

Risks

• Substantial doubt regarding the ability to continue as a going concern.
• Dependence on related-party financing to fund operations and service existing debt.
• Risk of litigation from creditors due to overdue promissory notes and interest payments.
• Reliance on third-party suppliers for CGM hardware and potential supply chain disruptions.
• Regulatory hurdles and the need for additional clearances for human health products.
• Intense competition in the diabetes management market from companies with significantly greater resources.

Future Outlook

The company plans to focus on the commercial launch of the GluCurve Pet CGM product in 2026 and subsequently advance the Diabetes Solution for human health, contingent upon securing necessary CGM hardware and additional financing.

Management Comments

• Management believes that recurring losses and other factors raise substantial doubt about the ability to continue as a going concern.
• Management intends to improve financial condition by increasing revenues through new markets, expanding sales forces, and reducing expenses.
• Management believes the business plan provides the best opportunity to achieve commercial feasibility, though there is substantial uncertainty regarding execution.

Industry Context

StockSavvy.ai notes that the company operates in a highly competitive and fragmented diabetes management market, where success is increasingly driven by integrated CGM technology and AI-driven analytics, areas where the company is currently struggling to gain traction against well-capitalized incumbents.

Comparison to Industry Standards

• Unlike established competitors such as Medtronic or Dexcom, the company lacks significant commercial revenue and relies heavily on related-party debt.
• The company's reliance on third-party CGM hardware contrasts with industry leaders who typically maintain vertically integrated or highly stable supply chains.
• The company's financial position is significantly weaker than industry benchmarks, characterized by a severe working capital deficit and recurring losses.

Corporate Governance

Legal Proceedings

• Multiple default judgments exist against the company regarding overdue promissory notes and interest.
• Ongoing risk of litigation from creditors due to failure to repay debt obligations.

Related Party Transactions

• Significant debt owed to CEO Sidney Chan, VP Christine Kan, and related entities.
• Ongoing interest payments and warrant modifications involving related parties.
• New line of credit and loan amendments with Kan Wan Chen Pte. Ltd. (KWC).

Stakeholder Impact

• Shareholders face substantial dilution risk from potential future equity raises and warrant exercises.
• Creditors face significant risk of non-payment given the company's financial distress.
• Employees and contractors are dependent on the company's ability to secure ongoing financing.

Next Steps

• Commercial launch of GluCurve Pet CGM product in 2026.
• Identification of viable CGM system supply for human health products.
• Continued efforts to secure additional financing to meet operating requirements.

Key Dates

Recommendation

The company's financial position is precarious, with substantial doubt regarding its survival, no revenue, and a massive debt load owed to insiders. A seasoned investor would likely avoid this equity due to the high risk of total loss.

Keywords

Diabetes Management, GluCurve, Continuous Glucose Monitoring, Medical Devices, ALRT, Biotech, Healthcare Technology